SLC5A2 and liver dysplastic nodule: Although renin-angiotensin system and SGLT2 inhibitors have transformed the treatment landscape for DN, a significant proportion of patients continue to experience disease progression (Perkovic et al., 2019; Heerspink et al., 2020), highlighting the urgent need for novel therapeutic strategies.